Form 4 for CRSP CRISPR Therapeutics AG

Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-14 · accession 0001193125-26-111281 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-03-17	2026-03-14	CRSP	KASINGER JAMES R.	GC, Sec	M - OptEx	—	+6,875	94.7K	+8%	—
D	2026-03-17	2026-03-16	CRSP	KASINGER JAMES R.	GC, Sec	S - Sale+OE	$48.26	-3,450	91.2K	-4%	-$166.5K
D	2026-03-17	2026-03-14	CRSP	KASINGER JAMES R.	GC, Sec	M - OptEx	—	-6,875	20.6K	-25%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2026-03-14	M	A	6,875	—	94,690	D	—	—	(F2) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
2	Common	Common Shares	2026-03-16	S	D	3,450	$48.26	91,240	D	—	—	(F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
3	Derivative	Restricted Stock Units	2026-03-14	M	D	6,875	—	20,625	D	— · — to —	6,875 Common Shares	(F2) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F4) This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.